摘要:
A method for producing organopolysiloxanes having unsaturated groups. Where the organopolysiloxanes produced include organopolysiloxanes (A), organopolysiloxanes (B), catalysts (D) and optionally organopolysiloxane compounds (C).
and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
摘要:
The present application provides an amphiphilic cyclodextrin-based compound of the formula I: R-G-D-A (I) wherein R is one or more hydrophilic groups; G is one or more linkers; D is a cyclodextrin, and A is one or more aliphatic groups. In certain embodiments, the hydrophilic group is a sugar such as lactose, the linker comprises —(CHR′CH2O)n— where R′ is H or is an alkyl group substituted with —(CHR′CH2O)n— where n is 1 to 20, typically n=4; the cyclodextrin is a β-cyclodextrin comprising 7 subunits, and the aliphatic groups are C6 alkyl groups. The compound can be used to enhance water solubility, bioavailability, cellular uptakes of active ingredients used in medicines, cosmetics and foods and other products, for detection, removal and immobilization of pathogenic organisms, toxins, and autoantibodies, and biomarkers on solid matrix, or for molecular biological techniques, such as ELISA, for example.
摘要:
In a first aspect, a composition of matter includes a substantially symmetrical 3-arm star block copolymer having a central core and diblock copolymer arms having inner blocks and outer blocks. In a second aspect, an article includes a substrate, a block copolymer composition on the substrate, and a neutral layer between the substrate and the block copolymer composition.
摘要:
Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.
摘要:
A wellbore strengthening composition may include a base fluid and at least one polymer functionalized with electrochemically activated groups. A method of treating a wellbore may include emplacing, in at least a selected region of the wellbore, a wellbore strengthening composition including a base fluid and at least one polymer functionalized with electrochemically activated groups. The method may also include emplacing a downhole tool capable of generating a voltage potential in the wellbore and applying a voltage potential in the wellbore with the downhole tool.
摘要:
Provided herein are methods of suppressing viral nucleic acid, e.g. double-stranded (ds) DNA, genome release from or packaging of viruses having their nucleic acid genome packaged under stress in their capsid, and compositions useful for that purpose. The methods alter the ionic environment of the nucleic acid within the capsid and thereby prevent release of, and/or interfere with packaging of the viral genome.
摘要:
The present invention relates to polyethylene compositions comprising one or more ethylene polymers and one or more dendritic hydrocarbon polymer modifiers, in particular, this invention further relates to polyethylene blends comprising one or more ethylene polymers and one or more dendritic hydrocarbon polymer modifiers, wherein the modifier has: 1) a g′ value less than 0.75; 2) a Cayley tree topology with a layer number of 2 or more more; and 3) a average Mw between the branch points of 1,500 g/mol or more.
摘要:
Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.
摘要:
A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjugated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugar selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one of the same and a combination thereof, wherein each sugar is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.